A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

por Khalil, Danny N., Prieto González-Albo, Isabel, Rosen, Lee, Lillie, Tom, Stacey, Andrea, Parfitt, Lola, Soff, Gerald A.
Publicado 2023

Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical tria...

por Fakih, Marwan, Harb, Wael, Mahadevan, Daruka, Babiker, Hani, Berlin, Jordan, Lillie, Tom, Krige, David, Carter, Jo, Cox, Chris, Patel, Minesh, Parfitt, Lola, Powell, Mark, Rosen, Lee
Publicado 2023